Bionano Genomics, Inc.

Equities

BNGO

US09075F3055

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 23/05/2024 am IST			5-day change	1st Jan Change
1.11 ^USD	+5.71%		-3.48%	-41.27%

09/05	Bionano Genomics, Inc. Announces Significant Upgrades to its Suite of Computational Tools for Comprehensive Cancer Analysis	CI
08/05	Transcript : Bionano Genomics, Inc., Q1 2024 Earnings Call, May 08, 2024

Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024

May 09, 2024 at 01:31 am IST

Bionano Genomics, Inc. provided revenue guidance for the second quarter of 2024 and reiterated revenue guidance for the year 2024. The revenue for the second quarter of 2024 is expected to be $7.8 to $8.2 million.

The company reiterated full year 2024 revenue guidance of $37.0 to $41.0 million.

Latest news about Bionano Genomics, Inc.

Bionano Genomics, Inc. Announces Significant Upgrades to its Suite of Computational Tools for Comprehensive Cancer Analysis	09/05	CI
Transcript : Bionano Genomics, Inc., Q1 2024 Earnings Call, May 08, 2024	09/05
Bionano Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024	09/05	CI
Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health	17/04	MT
Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence	17/04	CI
Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics	03/04	CI
Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting	02/04	CI
Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance	19/03	CI
Scotiabank Trims Price Target on Bionano Genomics to $6 From $7, Maintains Sector Outperform Rating	07/03	MT
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Transcript : Bionano Genomics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	06/03
Bionano Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03	CI
Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	06/03	CI
Bionano Genomics, Inc. announced that it has received $35 million in funding	27/02	CI
Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer	25/01	CI
Bionano Announces Full Commercial Release of the Stratys?? System for High Throughput Optical Genome Mapping	23/01	CI
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing	12/01	CI
Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	08/01	CI
Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via? Software for Ogm Data Analysis in Constitution Genetic Disease Research	28/12	CI
Bionano Genomics, Inc. Announces Publication of Largest Prospective Prenatal Study Comparing Ogm to Chromosomal Microarray Analysis and Karyotyping	26/12	CI
North American Morning Briefing : Caution -2-	14/11	DJ
Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023	09/11
Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023	09/11	CI

Chart Bionano Genomics, Inc.

Duration

Period

More charts

Company Profile

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Sector

Advanced Medical Equipment & Technology

Calendar

18/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Bionano Genomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.11 USD

Average target price

6.667 USD

Spread / Average Target

+500.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIONANO GENOMICS, INC.	-41.27%	7.42Cr
THERMO FISHER SCIENTIFIC	+11.31%	23TCr
DANAHER CORPORATION	+15.50%	20TCr
INTUITIVE SURGICAL, INC.	+18.83%	14TCr
BOSTON SCIENTIFIC CORPORATION	+30.38%	11TCr
SIEMENS HEALTHINEERS AG	+2.74%	6.53TCr
EDWARDS LIFESCIENCES CORPORATION	+18.31%	5.44TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.96%	5.09TCr
AGILENT TECHNOLOGIES, INC.	+9.95%	4.48TCr
GE HEALTHCARE TECHNOLOGIES INC.	+4.27%	3.68TCr

Other Advanced Medical Equipment & Technology